[{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"||CK2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"||CK2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"||CK2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Center for Advanced Research and Education","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Center for Advanced Research and Education","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Center for Advanced Research and Education"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Senhwa Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Senhwa Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ Senhwa Biosciences"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Pediatric Brain Tumor Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Pediatric Brain Tumor Consortium","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Pediatric Brain Tumor Consortium"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Pediatric Brain Tumor Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Pediatric Brain Tumor Consortium","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Pediatric Brain Tumor Consortium"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"||CK2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Senhwa Biosciences \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Silmitasertib
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
